

MERCY MEMORIAL HOSPITAL SYSTEM  
DEPARTMENT OF RADIOLOGY SERVICES  
ADMINISTRATION

FACSIMILE TRANSMITTAL SHEET

TO: MATERIAL LICENSING DATE: 8/4/08

COMPANY: NRC FROM: IMAGING SERVICES - OFFICE

FAX NUMBER: 630 829 9782 TELEPHONE: (734) 240-5600

PHONE NUMBER: FAX: (734) 240-5609

RE: LICENSE AMENDMENT NUMBER OF PAGES INCLUDING COVER: 6

URGENT  FOR REVIEW  PLEASE COMMENT  PLEASE REPLY  PLEASE RECYCLE

NOTES/COMMENTS:

\*\*\*\*\* CONFIDENTIALITY NOTICE \*\*\*\*\*

The documents accompanying this telecopy transmission may contain confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party and is required to destroy the information after its stated need has been fulfilled, unless otherwise required by state law.

If you are not the intended recipient, you are hereby notified that any disclosure copying, distribution or action taken in reference to the contents of these documents is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for return of these documents.

718 N. MACOMB STREET, MONROE, MICHIGAN 48162



July 11, 2008

UNITED STATES NUCLEAR REGULATORY COMMISSION  
Region III, Materials Licensing Section  
2443 Warrenville Road  
Suite 210  
Lisle, IL 60532-4352

Re: License number 21-18816-01

Please add Gerling Sauter, M.D. as an authorized user for 35.100, 35.200 and 35.300. Dr. Sauter is listed on license number 21-11850-01 Amendment No 40. This is enclosed for your review.

Thank you for your cooperation with this matter. If you have any questions or require additional information please contact our physicist, Michelle L. Kritzman, at (734) 662-3197.

Sincerely,

A handwritten signature in cursive script, appearing to read "Craig Kelly".

Administrative Officer  
Mercy Memorial Hospital  
Monroe, Michigan

*Corporate  
Connection*  
(734) 240-4150

*HomeCare  
Connection*  
(734) 240-1717

*Macomb  
Pharmacy*  
(734) 240-4100

*Outpatient  
Surgery Center*  
(734) 240-1900

*Rehabilitation  
Center*  
(734) 240-1950

*Family Center*  
(734) 240-1760

*Foundation*  
(734) 240-4488

*Home Respiratory*  
(734) 240-8888

*Hospice*  
(734) 240-8940

*Hospital*  
(734) 240-8400

*Nursing Center*  
(734) 240-1820

Jul. 10. 2008\_ 1:32PM

ST. JOSEPH'S HEALTHCARE

No. 2721 P. 2/5

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES  
Amendment No. 40

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

309598

<p>Licensee</p> <p>1. St. Joseph Hospital</p> <p>2. 15855 19 Mile Road Mt. Clemens, MI 48043</p>	<p>In accordance with letter dated <b>September 4, 2001</b></p> <p>3. License number 21-11850-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date <b>June 30, 2004</b></p> <hr/> <p>5. Docket No. <b>030-02106</b> Reference No. <b>2</b></p>
--	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material identified in 10 CFR 35.100</p> <p>B. Any byproduct material identified in 10 CFR 35.200</p> <p>C. Any byproduct material identified in 10 CFR 35.300</p> <p>D. Any byproduct material identified in 10 CFR 31.11</p> <p>E. Americium-241</p> <p>F. Palladium-103</p> <p>G. Iodine-125</p>	<p>7. Chemical and/or physical form</p> <p>A. Any radiopharmaceutical identified in 10 CFR 35.100</p> <p>B. Any radiopharmaceutical identified in 10 CFR 35.200</p> <p>C. Any radiopharmaceutical identified in 10 CFR 35.300</p> <p>D. Prepackaged Kits</p> <p>E. Sealed source (Amersham/Searle Model No. AMC 24)</p> <p>F. As identified in 10 CFR 35.400</p> <p>G. As identified in 10 CFR 35.400</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. <input checked="" type="radio"/> As needed</p> <p>B. <input type="radio"/> As needed</p> <p>C. <input checked="" type="radio"/> As needed</p> <p>D. <input type="radio"/> As needed</p> <p>E. 2 sources not to exceed 14 millicuries each</p> <p>F. 700 millicuries</p> <p>G. 500 millicuries</p>
--	---	---

<p>9. Authorized Use:</p> <p>A. Medical use described in 10 CFR 35.100.</p> <p>B. Medical use described in 10 CFR 35.200.</p>
---

Jul. 10. 2008\_ 1:33PM ST. JOSEPH'S HEALTHCARE

No. 2721 P. 3/5

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 4 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
21-11850-01Docket or Reference Number  
030-02106

Amendment No. 40

- C. Medical use described in 10 CFR 35.300.
- D. In vitro studies.
- E. For use as anatomical markers.
- F. and G. Any manual brachytherapy procedure approved in 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.

10. Location of Use: St. Joseph Hospitals at 215 North Avenue, Mt. Clemens, Michigan and 15855 19 Mile Road, Mt. Clemens, Michigan.

11. A. Radiation Safety Officer: Harold C. Papson, M.D.

B. Radiation Safety Officer (Palladium-103 and iodine-125 only): Lisa Langenstein, M.S.

12. Authorized Users:

Harold C. Papson, M.D. 10 CFR 35.100, 35.200, 35.300, and 31.11.

Wook-Chin Chong, M.D. 10 CFR 35.100, 35.200, 35.300, and 31.11.

Gerling Sauter, M.D. 10 CFR 35.100, 35.200, 35.300, and 31.11.

Bhaskar Shenai, M.D. 10 CFR 35.100, 35.200 and 35.300.

Tae Sik Yook, M.D. 31.11.

Jayant I. Shah, M.D. 31.11.

Christopher K. Shier, M.D. 10 CFR 35.100 and 35.200.

Jadranka Dragovic, M.D. Palladium-103 and iodine-125 for uses identified in 10 CFR 35.400

Cynthia Wheeler, M.D. 10 CFR 35.100, 35.200, and 35.300.

Eleanor Walker, M.D. Palladium-103 and iodine-125 for uses identified in 10 CFR 35.400

Mark Khil, M.D. Palladium-103 and iodine-125 for uses identified in 10 CFR 35.400.

Anatoly Zelikov, M.D. Palladium-103 and iodine-125 for uses identified in 10 CFR 35.400

Jul. 10. 2008 1:33PM

ST. JOSEPH'S HEALTHCARE

No. 2721 P. 4/5

NRC FORM 314A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 4 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

21-11850-01

Docket or Reference Number

030-02106

Amendment No. 40

13. A. (1) The source(s) specified in Item(s) 7.F. shall be tested for leakage and/or contamination at intervals not to exceed 6 months. Any source received from another person which is not accompanied by a certificate indicating that a test was performed within 6 months before the transfer shall not be put into use until tested.
- (2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.
- B. Any source in storage and not being used need not be tested. When the source is removed from storage for use or transfer to another person, it shall be tested before use or transfer.
- C. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the source shall be removed from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. A report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region III, 801 Warrenville Road, Lisle, Illinois 60532, ATTN: Chief, Nuclear Materials Safety Branch. The report shall specify the source involved; the test results; and corrective action taken. Records of leak test results shall be kept in units of microcuries and shall be maintained for inspection by the Commission. Records may be disposed of following Commission inspection.
- D. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Commission or an Agreement State to perform such services.
14. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. The licensee shall implement the model procedure for radiation safety during implant therapy published in Appendix Q to Regulatory Guide 10.8, Revision 2.
16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

Jul. 10. 2008 1:33PM ST. JOSEPH'S HEALTHCARE

No. 2721 P. 5/5

NRC FORM 314A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 4 PAGES


**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
21-11850-01

Docket or Reference Number  
030-02105

Amendment No. 40

- A. Application dated January 4, 1994 (excluding any reference made to QMP); and
- B. Letters dated May 26, 1994 and February 23, 1995, June 13, 1995, September 30, 1996, and January 25, 1999 (except attached Quality Management Program Brachytherapy Module).



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date SEP 19 2001

By Charles F. Gill

Charles F. Gill  
Materials Licensing Branch  
Region III